SKYSCRAPER-01:替瑞利尤单抗联合阿替利珠单抗治疗初治PD-L1高表达晚期非小细胞肺癌
SKYSCRAPER-01是一项III期随机研究,评估替瑞利尤单抗联合阿替利珠单抗对比安慰剂联合阿替利珠单抗在初治PD-L1高表达局部晚期不可切除或转移性NSCLC中的疗效与安全性。结果显示,联合组INV-PFS和OS均未达到统计学显著获益,两组安全性事件发生率相似。
要点
- 替瑞利尤单抗联合阿替利珠单抗未显著改善PD-L1高表达NSCLC的INV-PFS或OS。
- 联合组与对照组3-4级不良事件发生率分别为41.2%和33.8%。
- 该联合方案不优于阿替利珠单抗单药,不支持在初治PD-L1高表达NSCLC中常规联合使用。
核心结论
- 在初治PD-L1高表达晚期非小细胞肺癌中,替瑞利尤单抗联合阿替利珠单抗相比阿替利珠单抗单药未显示统计学显著的INV-PFS或OS获益。
研究设计与样本
- 主要终点为研究者评估的无进展生存期(INV-PFS)和总生存期(OS),主要分析集为22C3检测PD-L1高表达人群。
主要发现
- 联合组与对照组分别有41.2%(110/267)和33.8%(89/263)的患者发生3-4级不良事件,治疗相关死亡分别为4例和2例。
临床怎么用
- 对于初治PD-L1高表达晚期NSCLC,不应常规推荐替瑞利尤单抗联合阿替利珠单抗,阿替利珠单抗单药仍是该人群的合理选择。
- 联合方案未显著改善生存且3-4级不良事件发生率略高,临床决策需权衡获益与风险。
局限性
- 原文未报告其他亚组分析结果,联合方案在特定亚组中的潜在获益尚不明确。
- 中位随访时间在PFS分析时为9.9个月、OS分析时为17.9个月,长期生存数据仍需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tiragolumab plus atezolizumab has shown encouraging survival outcomes in metastatic non-small cell lung cancer (NSCLC), primarily in patients with PD-L1-high tumors. We further evaluated the combination of tiragolumab plus atezolizumab in the phase III SKYSCRAPER-01 study. METHODS: Patients with untreated, locally advanced unresectable/metastatic PD-L1-high (by central laboratory testing) NSCLC were randomly assigned 1:1 to receive either tiragolumab (600 mg) plus atezolizumab (1,200 mg) or placebo plus atezolizumab (1,200 mg) intravenously in 21-day cycles until disease progression, loss of clinical benefit, or unacceptable toxicity. Primary end points were investigator-assessed progression-free survival (INV-PFS) and overall survival (OS) in the primary analysis set (PD-L1-high per 22C3 assay). RESULTS: Five hundred twenty-one patients were randomly assigned to either the tiragolumab plus atezolizumab group (n = 262) or the placebo plus atezolizumab group (n = 259). At the primary PFS analysis (Mar 12, 2022; median follow-up 9.9 months [IQR, 6.2-13.8]), median INV-PFS was 7.0 months (95% CI, 5.6 to 9.8) with tiragolumab plus atezolizumab and 5.6 months (95% CI, 4.4 to 7.0) with placebo plus atezolizumab (hazard ratio [HR], 0.78 [95% CI, 0.63 to 0.97]; P = .02 [nonsignificant]). At the final OS analysis (Sept 24, 2024; median follow-up 17.9 months [IQR, 6.7-39.0]), median OS was 23.1 months (95% CI, 17.7 to 28.8) with tiragolumab plus atezolizumab and 16.9 months (95% CI, 14.6 to 21.3) with placebo plus atezolizumab (HR, 0.87 [95% CI, 0.7 to 1.1]; P = .22 [nonsignificant]). Overall, 41.2% (n = 110/267) and 33.8% (n = 89/263) of patients experienced grade 3-4 adverse events with tiragolumab plus atezolizumab and placebo plus atezolizumab, respectively. Four and two treatment-related deaths occurred in each group, respectively. CONCLUSION: Tiragolumab plus atezolizumab did not demonstrate a statistically significant INV-PFS or OS benefit over atezolizumab in patients with previously untreated PD-L1-high NSCLC.
引用
- Peters S, Herbst R, Horinouchi H, et al. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2026. PMID: 42507968. doi:10.1200/JCO-25-02777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。